With Celgene buyout, Juno CEO Hans Bishop set for monster payout of $287M

7 years ago

by David Miller

960 Views

Written by David Miller

After ushering Juno Therapeutics through early fundraising, an IPO, clinical setbacks and more, CEO Hans Bishop is set to take home up to $287 million when the CAR-T player seals its buyout with Celgene.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller

Don`t Leave Yet!